EP1406930A4 - "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF" - Google Patents

"ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"

Info

Publication number
EP1406930A4
EP1406930A4 EP01994330A EP01994330A EP1406930A4 EP 1406930 A4 EP1406930 A4 EP 1406930A4 EP 01994330 A EP01994330 A EP 01994330A EP 01994330 A EP01994330 A EP 01994330A EP 1406930 A4 EP1406930 A4 EP 1406930A4
Authority
EP
European Patent Office
Prior art keywords
epitopes
antibodies
isolated molecules
containing sulfated
sulfated moieties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01994330A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1406930A2 (en
Inventor
Janette Lazarovits
Yocheved Hagai
Daniel Plaksin
Tikva Vogel
Abraham Nimrod
Hagit Mar-Haim
Ester Szanthon
Tamar Richter
Boaz Amit
Lena Kooperman
Tuvia Peretz
Avigdor Levanon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Savient Pharmaceuticals Inc
Original Assignee
Savient Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Savient Pharmaceuticals Inc filed Critical Savient Pharmaceuticals Inc
Publication of EP1406930A2 publication Critical patent/EP1406930A2/en
Publication of EP1406930A4 publication Critical patent/EP1406930A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP01994330A 2000-12-29 2001-12-31 "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF" Withdrawn EP1406930A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US751181 1996-11-15
US75118100A 2000-12-29 2000-12-29
US25894800P 2000-12-29 2000-12-29
US258948P 2000-12-29
PCT/US2001/049442 WO2002053700A2 (en) 2000-12-29 2001-12-31 Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof

Publications (2)

Publication Number Publication Date
EP1406930A2 EP1406930A2 (en) 2004-04-14
EP1406930A4 true EP1406930A4 (en) 2007-01-10

Family

ID=26946974

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01994330A Withdrawn EP1406930A4 (en) 2000-12-29 2001-12-31 "ISOLATED MOLECULES WITH SULFATED GROUPING CONTAINING EPITOPES, ANTIBODIES AGAINST SUCH EPITOPES AND USES THEREOF"

Country Status (13)

Country Link
EP (1) EP1406930A4 (ja)
JP (1) JP2005503756A (ja)
KR (1) KR20030091953A (ja)
CN (1) CN100347194C (ja)
BR (1) BR0116764A (ja)
CA (1) CA2433225A1 (ja)
CZ (1) CZ20031982A3 (ja)
HU (1) HUP0700079A2 (ja)
IL (1) IL156689A0 (ja)
MX (1) MXPA03005945A (ja)
PL (1) PL366223A1 (ja)
RU (1) RU2003123101A (ja)
WO (1) WO2002053700A2 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
CA2491427A1 (en) * 2002-07-01 2004-01-08 Savient Pharmaceuticals, Inc. Compositions and methods for therapeutic treatment
CA2531283A1 (en) * 2003-06-30 2005-01-20 Bio-Technology General (Israel) Ltd. Specific human antibodies
MXPA06000252A (es) * 2003-06-30 2006-12-15 Bio Technology General Israel Anticuerpos y usos de los mismos.
ITMI20031714A1 (it) * 2003-09-05 2005-03-06 Gentium Spa Formazioni ad azione antitumorale.
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
CA2565872C (en) * 2004-05-11 2016-06-21 Abgenomics Corporation T-cell death-inducing epitopes
CN103260627A (zh) 2010-11-12 2013-08-21 真蒂奥姆有限公司 去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
DK2864496T4 (da) 2012-06-22 2021-01-04 Gentium S R L Euglobulin-baseret fremgangsmåde til bestemmelse af den biologiske aktivitet af defibrotid
WO2016013828A1 (ko) * 2014-07-21 2016-01-28 연세대학교 산학협력단 황산화된 더피 케모카인 수용체의 세포 외 도메인 1 변이체 및 이의 용도
EP3026122A1 (en) 2014-11-27 2016-06-01 Gentium S.p.A. Cellular-based method for determining the potency of defibrotide
JP2019031486A (ja) * 2017-08-04 2019-02-28 公立大学法人福島県立医科大学 新規ポリペプチド及びその用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011778A1 (en) * 1991-12-12 1993-06-24 The Scripps Research Institute Bifunctional antithrombotic molecules and antithrombotic polypeptides
WO1997000079A1 (en) * 1995-06-14 1997-01-03 The General Hospital Corporation P-selectin ligands and related molecules and methods
WO1997006176A2 (en) * 1995-08-03 1997-02-20 Board Of Regents Of The University Of Oklahoma Peptide and o-glycan inhibitors of selectin mediated inflammation
WO1998012318A1 (en) * 1996-09-17 1998-03-26 Wisconsin Alumni Research Foundation Thrombin inhibitor
WO1999065712A2 (en) * 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptides and methods of synthesis and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993011778A1 (en) * 1991-12-12 1993-06-24 The Scripps Research Institute Bifunctional antithrombotic molecules and antithrombotic polypeptides
WO1997000079A1 (en) * 1995-06-14 1997-01-03 The General Hospital Corporation P-selectin ligands and related molecules and methods
WO1997006176A2 (en) * 1995-08-03 1997-02-20 Board Of Regents Of The University Of Oklahoma Peptide and o-glycan inhibitors of selectin mediated inflammation
WO1998012318A1 (en) * 1996-09-17 1998-03-26 Wisconsin Alumni Research Foundation Thrombin inhibitor
WO1999065712A2 (en) * 1998-06-16 1999-12-23 The Board Of Regents Of The University Of Oklahoma Glycosulfopeptides and methods of synthesis and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JIROUSKOVA MARKETA ET AL: "A hamster antibody to the mouse fibrinogen gamma chain inhibits platelet-fibrinogen interactions and FXIIIa-mediated fibrin cross-linking, and facilitates thrombolysis", THROMBOSIS AND HAEMOSTASIS, vol. 86, no. 4, October 2001 (2001-10-01), pages 1047 - 1056, XP009068292, ISSN: 0340-6245 *
JIROUSKOVA MARKETA ET AL: "Antibody blockade or mutation of the fibrinogen gamma-chain C-terminus is more effective in inhibiting murine arterial thrombus formation than complete absence of fibrinogen.", BLOOD, vol. 103, no. 6, 15 March 2004 (2004-03-15), pages 1995 - 2002, XP002386678, ISSN: 0006-4971 *
LENGWEILER STEPHAN ET AL: "Preparation of monoclonal antibodies to murine platelet glycoprotein IIb/IIIa (alphaIIbbeta3) and other proteins from hamster-mouse interspecies hybridomas", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 262, no. 1, 19 August 1999 (1999-08-19), pages 167 - 173, XP002386677, ISSN: 0006-291X *
SCHEINER T ET AL: "A monoclonal antibody to the fibrinogen gamma-chain alters fibrin clot structure and its properties by producing short, thin fibers arranged in bundles.", JOURNAL OF THROMBOSIS AND HAEMOSTASIS : JTH. DEC 2003, vol. 1, no. 12, December 2003 (2003-12-01), pages 2594 - 2602, XP009068271, ISSN: 1538-7933 *

Also Published As

Publication number Publication date
BR0116764A (pt) 2007-01-09
WO2002053700A2 (en) 2002-07-11
WO2002053700A3 (en) 2004-02-12
EP1406930A2 (en) 2004-04-14
IL156689A0 (en) 2004-01-04
PL366223A1 (en) 2005-01-24
MXPA03005945A (es) 2004-10-15
CA2433225A1 (en) 2002-07-11
KR20030091953A (ko) 2003-12-03
CN100347194C (zh) 2007-11-07
JP2005503756A (ja) 2005-02-10
HUP0700079A2 (en) 2007-05-02
RU2003123101A (ru) 2005-03-10
CZ20031982A3 (cs) 2004-09-15
CN1649900A (zh) 2005-08-03

Similar Documents

Publication Publication Date Title
MXPA03001590A (es) Anticuerpos para la il-1beta humana.
HUP0302376A3 (en) Anti-tnf antibodies, compositions, methods and uses
HUP0302128A3 (en) Anti-dual integrin antibodies, compositions, methods and uses
ZA200400521B (en) Antibodies to OPGL.
EG25801A (en) Antibodies to CD 40
ZA200207589B (en) Multivalent antibodies and uses therefor. Multivalent antibodies and uses thereof.
AU3662101A (en) Cd40-binding apc-activating molecules
GB0029360D0 (en) Humanised antibodies and uses thereof
IL156689A0 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
GB0002093D0 (en) Antiperspirants
AU2002365894A8 (en) Antibodies to magmas and uses thereof
GB0115428D0 (en) Antibodies, peptides, analogs and uses thereof
MXPA03005511A (es) Toallitas antitranspirantes.
AU2002221132A1 (en) Novel antibody
GB0022670D0 (en) Molecules
GB0002625D0 (en) Dendroaspin molecules
GB0031284D0 (en) High affinity antibodies
GB0020568D0 (en) Novel antibody
AU8557801A (en) Modified proteins, isolated novel peptides, and uses thereof
AU2001236588A1 (en) Antibodies to the staphylococcal multidrug resistance (smr) protein
GB0005071D0 (en) Antibodies
GB0019640D0 (en) Improvements to bottle
GB0005728D0 (en) Conserved antigens
GB0009538D0 (en) Antibody binding
GB0008160D0 (en) Monoclonal antibodies

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030728

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SAVIENT PHARMACEUTICALS, INC.

A4 Supplementary search report drawn up and despatched

Effective date: 20061211

17Q First examination report despatched

Effective date: 20070403

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20090701